Jiaji Mao1,2, Dabiao Deng3, Zehong Yang1, Wensheng Wang3, Minghui Cao1, Yun Huang4, Jun Shen1,2. 1. Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, China. 2. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, China. 3. Department of Medical Imaging, Guangdong 999 Brain Hospital, No. 578 Shatai Road South, Guangzhou, China. 4. Department of Medical Statistics, School of Public Health, Sun Yat-Sen University, No. 74 Zhongshan II Road, Guangzhou, China.
Abstract
OBJECTIVES: To determine the performance of pretreatment structural and arterial spin labelling (ASL) MRI in predicting p53 mutation in patients with high-grade gliomas (HGGs). METHODS: Pre-treatment structural and ASL MRI were performed in 57 patients with histologically confirmed HGGs and information of p53 status. Whole-lesion histogram analysis of cerebral blood flow (CBF) images of the enhancing tumour and the peritumoral oedema in the HGGs were performed. Visually AcceSAble Rembrandt Images features were used as qualitative analysis. The differences of ASL histogram parameters and Visually AcceSAble Rembrandt Images features between HGGs with or without p53 mutation were analyzed with post hoc correction for multiple comparisons. LASSO regression was performed to select the optimal features that could predict p53 mutation, followed by receiver operating characteristic analysis to determine the predictive efficacy. RESULTS: A total of 33 HGGs with p53 mutation and 24 without p53 mutation were included. HGGs with mutant p53 showed lower CBFpercentile5 and CBFuniformity of the enhancing tumour (p < 0.05) and higher prevalence of the qualitative MRI feature of enhancing tumour crossing midline (ETCM) (p < 0.05) as compared with HGGs with wild-type p53. LASSO regression showed that the CBFuniformity of the enhancing tumour and ETCM were predictive features for p53 mutation. CBFuniformity showed an acceptable performance in predicting p53 mutation (area under the curve = 0.721), when combined with the feature of ETCM, its predictive efficacy was significantly improved (area under the curve = 0.814, p = 0.012). CONCLUSION: An integrated pre-treatment structural and ASL MRI can help to predict p53 mutation in HGGs.
OBJECTIVES: To determine the performance of pretreatment structural and arterial spin labelling (ASL) MRI in predicting p53 mutation in patients with high-grade gliomas (HGGs). METHODS: Pre-treatment structural and ASL MRI were performed in 57 patients with histologically confirmed HGGs and information of p53 status. Whole-lesion histogram analysis of cerebral blood flow (CBF) images of the enhancing tumour and the peritumoral oedema in the HGGs were performed. Visually AcceSAble Rembrandt Images features were used as qualitative analysis. The differences of ASL histogram parameters and Visually AcceSAble Rembrandt Images features between HGGs with or without p53 mutation were analyzed with post hoc correction for multiple comparisons. LASSO regression was performed to select the optimal features that could predict p53 mutation, followed by receiver operating characteristic analysis to determine the predictive efficacy. RESULTS: A total of 33 HGGs with p53 mutation and 24 without p53 mutation were included. HGGs with mutant p53 showed lower CBFpercentile5 and CBFuniformity of the enhancing tumour (p < 0.05) and higher prevalence of the qualitative MRI feature of enhancing tumour crossing midline (ETCM) (p < 0.05) as compared with HGGs with wild-type p53. LASSO regression showed that the CBFuniformity of the enhancing tumour and ETCM were predictive features for p53 mutation. CBFuniformity showed an acceptable performance in predicting p53 mutation (area under the curve = 0.721), when combined with the feature of ETCM, its predictive efficacy was significantly improved (area under the curve = 0.814, p = 0.012). CONCLUSION: An integrated pre-treatment structural and ASL MRI can help to predict p53 mutation in HGGs.
Authors: Thoralf Thamm; Jia Guo; Jarrett Rosenberg; Tie Liang; Michael P Marks; Soren Christensen; Huy M Do; Stephanie M Kemp; Emma Adair; Irina Eyngorn; Michael Mlynash; Tudor G Jovin; Bart P Keogh; Hui J Chen; Maarten G Lansberg; Gregory W Albers; Greg Zaharchuk Journal: Stroke Date: 2019-10-17 Impact factor: 7.914
Authors: Bo Hong; A Pieter J van den Heuvel; Varun V Prabhu; Shengliang Zhang; Wafik S El-Deiry Journal: Curr Drug Targets Date: 2014-01 Impact factor: 3.465
Authors: Emeline Gillet; Agusti Alentorn; Brahima Doukouré; Emeline Mundwiller; Hinke F van Thuijl; Hinke van Thuij; Jaap C Reijneveld; José Alfonso Meza Medina; Amélie Liou; Yannick Marie; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Ahmed Idbaih Journal: J Neurooncol Date: 2014-03-04 Impact factor: 4.130
Authors: Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu Journal: Science Date: 2004-01-02 Impact factor: 47.728
Authors: Kai Roman Laukamp; Frank Thiele; Georgy Shakirin; David Zopfs; Andrea Faymonville; Marco Timmer; David Maintz; Michael Perkuhn; Jan Borggrefe Journal: Eur Radiol Date: 2018-06-25 Impact factor: 5.315
Authors: Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-05 Impact factor: 6.639